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Abstract: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH) are strongly associated with obesity, insulin
resistance, and type 2 diabetes. We recently developed and validated a
self-assessment score in the Korean population to identify people at high
risk for diabetes. The objective of this study was to evaluate whether the
self-assessment risk score for diabetes can also be used to screen for the
presence of NAFLD or NASH.
The study population included 15,676 subjects (8313 men and 7363
women) over 20 years old who visited the National Health Insurance
Service Ilsan Hospital in Korea between 2008 and 2010. Anthropo-
metric, clinical, and laboratory data were analyzed during regular health
checkups. Fatty liver disease was diagnosed using ultrasound, discrimi-
nation capability was assessed based on the area under the receiver
operating characteristic curve (AUC), and evaluation measures, includ-
ing sensitivity and specificity, were calculated. Multiple logistic
analyses were also performed.
We calculated a self-assessed risk score for diabetes (range: 0–11),
and a cutoff of5 identified 60% (50%) of men (women) at high risk for
NAFLD, reflecting a sensitivity of 79% (85%), a specificity of 60%
(66%), a positive predictive value (PPV) of 68% (51%), and a negative
predictive value (NPV) of 73% (91%), with an AUC of 0.75 (0.82) for
men (women). A cutoff point of 6 identified 43% (31%) of men
(women) at high risk for NASH, reflecting a sensitivity of 80% (86%), a
specificity of 64% (75%), a PPV of 30% (28%), and a NPV of 94%
(98%), with an AUC of 0.77 (0.86) for men (women). The odds ratios, MD, PhD, Bong- PhD,
and Dae Jung Kim, MD
respectively, in men, and 1.28 (95% CI: 1.21–1.34) and 1.89 (95%
CI: 1.73–2.07), respectively, in women.
The present study indicates that our self-assessment risk score for
diabetes could be an effective primary screening tool for the presence of
NAFLD or NASH.
(Medicine 94(27):e1103)
Abbreviations: AAR = aspartate transaminase/alanine
transaminase ratio, ALT = alanine transaminase, APRI =
aspartate transaminase-to-platelet ratio index, AST = aspartate
transaminase, AUC = area under the receiver operating
characteristic curve, BMI = body mass index, CIs = confidence
intervals, HDL = high-density lipoprotein, KDS = Korean Diabetes
Score, LDL = low-density lipoprotein, LRs = likelihood ratios,
NAFLD = nonalcoholic fatty liver disease, NASH = nonalcoholic
steatohepatitis, NPV = negative predictive value, ORs = odds
ratios, PPV = positive predictive value, ROC = receiver operating
characteristic, T2D = type 2 diabetes, TG = triglyceride, TyG = The
product of fasting triglycerides and glucose levels.
INTRODUCTION
O besity, one of the most rapidly increasing health problemsin the world,1 is associated with morbidity and mortality,
and contributes to the burden placed on society by chronic public
health conditions.2,3 Obesity has been identified as a leading
contributor to insulin resistance,4,5 and many previous studies
have shown that insulin resistance is strongly associated with the
development of type 2 diabetes (T2D) and nonalcoholic fatty
liver disease (NAFLD).6–9 Furthermore, nonalcoholic steatohe-
patitis (NASH) has also been associated with insulin resistance
syndrome, including obesity, T2D, and hypertriglyceride-
mia.10,11 NAFLD can transition to NASH as a function of the
progression of hepatic damage, inflammation, and fibrosis, and
NASH can develop into cirrhosis, and ultimately, hepatic can-
cer.12–14 In view of the impact of the various complications of
NAFLD and NASH, the early diagnosis of these conditions is an
important clinical issue facing public healthcare systems. How-
ever, NAFLD and NASH are difficult to diagnose in clinical
practice due to the need for an invasive procedure, that is, a liver
biopsy. Although several simple, noninvasive clinical scoring
systems for predicting NAFLD or NASH have been proposed,
they are not widely used because they involve a blood assay and
complex scoring formulas.15–18 Also, recently noninvasive tools
such as abdominal ultrasonography or transient elastography for
accessing liver steatosis or fibrosis have used yet, further con-anted and costs are high.19,20
loped and validated a self-assessment
risk that does not require blood assays or
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1–4.9 drinks as 1, and 5 drinks as 2; and family history ofmathematical calculations.21 The model includes age, family
history of diabetes, hypertension, waist circumference,
smoking status, and daily alcohol consumption, but does
not incorporate laboratory parameters. A recent study found
that this model was also validated as a predictor of predia-
betes as well as of T2D.22 Therefore, given that insulin
resistance is common to both NAFLD and NASH, the aim
of this study was to investigate and validate this diabetes risk
score for the prediction of these conditions in the adult
population.
METHODS
The Study Population
Between 2008 and 2010, 18,765 individuals aged over 20
years who visited the National Healthcare Insurance Ilsan
Medical Center (NHIMC) in Ilsan, South Korea for compre-
hensive health examinations were included on this study. Exclu-
sion criteria were as follows: history of alcohol abuse as
indicated by weekly alcohol consumption >140 g for males
and>70 g/week for females (N¼ 778); any etiological markers
for chronic liver disease, including positive serologic markers
for hepatitis B virus (N¼ 752), hepatitis C virus (N¼ 130), or
human immunodeficiency virus (N¼ 1); presence of thyroid
disease, including hyperthyroidism, hypothyroidism, or thyroid
hormone replacement therapy (N¼ 118); abnormal ultrasono-
graphic liver findings (ie, suspected hepatocellular carcinoma,
hepatic mass, or signs of Clonorchis sinensis) (N¼ 971); and/or
absence of questionnaire data or anthropometric measurements
(N¼ 1135). Data from a total of 15,676 individuals were
analyzed in this study.
The protocol of this study was approved by the Institu-
tional Review Board of the Ilsan Hospital, and written informed
consent for this study was not required because researchers
accessed only the database for purposes of analysis, and
personal information was not used.
Data and Measurements
All participants provided data regarding their demographic
characteristics; personal and family medical history; social
habits, including smoking and alcohol consumption; physical
activity; and use of medication at the time of their clinical
consultation. Body mass index (BMI) was calculated by weight
(kg)/height (m2). Waist circumference was obtained at the
minimal point between the lowest rib and the upper iliac crest
after normal expiration. Laboratory parameters were also
measured after overnight fasting. The product of fasting trigly-
cerides and glucose levels (TyG), a surrogate for identifying
insulin resistance, was estimated as the Ln[fasting triglycerides
(mg/dL) fasting glucose (mg/dL)/2].23 Subjects were classi-
fied as having diabetes if they were taking an oral hypoglycemic
agent or insulin, or had been previously diagnosed with diabetes
by a healthcare professional. Impaired fasting glucose was
defined as a fasting plasma glucose level of 100–125mg/dL
as per the 2011 revision of the American Diabetes Association
(ADA) guidelines.24 Hypertension was defined as taking anti-
hypertensive medication or having been diagnosed with this
condition by a physician. Individuals were categorized with
regard to smoking status according to self-reports as follows:
never, ex-smoker, and current smoker. Daily alcohol consump-
Kim et altion was quantified by types of beverages, frequency of drink-
ing, and average amount of alcohol consumed on each occasion,
as previously described.21 After excluding subjects with
2 | www.md-journal.comexcessive alcohol intake, alcohol consumption was classified
based on the daily amount of alcohol consumption: none, <1,
1–4.9, or 5 drinks daily. Exercise status was assessed by self-
reported questionnaires that included questions about the
duration, frequency, and types of exercise. Regular exercise
was then defined as engaging in physical activity for at least
30minutes at least twice weekly.
All subjects underwent abdominal ultrasonography (Sono-
line Antares MSC 2704 AB; Siemens Medical Solutions,
Issaquah, WA) performed by trained radiologists who were
blind to the patients’ clinical and laboratory data using a 3.5-
MHz transducer. The severity of the fatty liver was classified
into 3 grades (mild, moderate, and severe) according to standard
criteria.25 We also recorded the absence or presence of fatty
liver disease.
Due to its invasiveness, a liver biopsy was not performed,
and liver fibrosis was identified using previously reported
NAFLD fibrosis scores based on the following formula: –
1.675þ 0.037 age (years)þ 0.094BMI (kg/m2)þ 1.13
impaired fasting glucose (IFG)/diabetes (yes¼ 1, no¼ 0)þ
0.99 aspartate transaminase (AST)/alanine transaminase
(ALT) ratio – 0.013 platelet (109/L) – 0.66 albumin
(g/dL).16 Liver fibrosis was classified based on NAFLD fibrosis
scores: –1.445 to 0.676 was coded as indeterminate fibrosis,
and >0.676 was coded as advanced fibrosis.16
The Korean Diabetes Score (KDS) questionnaire was
administered to individuals by registered interviewers. As pre-
viously described,21 points were accrued for the following
parameters: age: <35 years was scored as 0, 35–44 years as
2, and 45 years as 3; waist circumference: percentiles 1–50
were scored as 0, percentiles 51–74 as 2, and 75th percentile
and above as 3; daily alcohol intake: <1 drink was scored as 0,
Medicine  Volume 94, Number 27, July 2015diabetes, history of hypertension, and smoking status were
scored as 0 or 1.
Statistical Analyses
All continuous variables are presented as means standard
deviations (SDs), and categorical variables are expressed as
frequencies with percentages. Differences were analyzed using
analysis of variance (ANOVA) for continuous variables and
Chi-square tests for categorical variables. The ability of the
KDS to predict NAFLD and NASH were evaluated by receiver
operating characteristic (ROC) curves. The area under the
receiver operating characteristic curve (AUC) was used to
compare the accuracy of tests in terms of their ability to make
relevant distinctions. In addition, we compared the performance
of the KDS using the following screening models for NAFLD or
NASH: FIB-4, [ageAST (IU/L)/platelet count (109/
L)ALT (IU/L)1/2]18; APRI (AST-to-platelet ratio index),
[(AST/upper limit of normal)/platelet count (109/L) 100]17;
and AAR (AST/ALT ratio).26 Data on sensitivity, specificity,
positive predictive value (PPV), negative predictive value
(NPV), likelihood ratios (LRs; positive and negative), the
Youden Index, and the AUC were analyzed to evaluate the
measures.21,27,28 The odds ratios (ORs) and 95% confidence
intervals (CIs) for the factors associated with the prevalence of
NAFLD or NASH were calculated using multiple logistic
regression analysis. A P< 0.05 was considered statistically
significant. Statistical analyses were performed using SAS
version 9.2 (SAS Institute, Cary, NC), SPSS version 20.0 (SPSS,
Chicago, IL), and MedCalc (version 13.1; http://medcalc.
software.informer.com/13.1/).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Baseline Characteristics of the Subjects
No Steatosis
(N¼ 9221)
Simple Steatosis
(N¼ 4386)
Steatohepatitis
(N¼ 2069) P-Value
Age, years 46.1 11.3 46.6 9.2 58.7 10.6 <0.001
Sex, M/F (% male) 4054/5167 (44) 2917/1469 (67) 1342/727 (65) <0.001
BMI, kg/m2 22.3 2.5 25.6 2.7 26.5 2.9 <0.001
BMI 25, kg/m2 (%) 1257 (14) 2454 (56) 1419 (69) <0.001
Waist circumference, cm 78.7 7.4 87.7 7.1 90.7 7.2 <0.001
Fasting glucose, mg/dL 90.5 13.5 96.0 19.1 112.3 28.4 <0.001
Total cholesterol, mg/dL 186.3 33.0 203.2 36.3 197.8 38.4 <0.001
Triglycerides, mg/dL 89.0 54.3 153.9 97.5 158.6 133.7 <0.001
HDL cholesterol, mg/dL 51.0 13.5 42.5 10.3 43.4 11.0 <0.001
LDL cholesterol, mg/dL 117.5 29.5 129.9 34.6 122.8 35.4 <0.001
Uric acid, mg/dL 4.9 1.2 5.7 1.4 5.5 1.4 <0.001
AST, IU/L 22.9 12.7 27.6 10.8 30.1 20.8 <0.001
ALT, IU/L 20.0 15.8 33.1 21.8 30.5 24.4 <0.001
Albumin, mg/dL 4.2 0.3 4.3 0.3 4.2 0.3 <0.001
TyG value 8.15 0.56 8.74 0.59 8.89 0.64 <0.001
Hypertension, % 1425 (15) 1180 (27) 1069 (52) <0.001
Diabetes, % 294 (3) 257 (6) 628 (30) <0.001
Impaired fasting glucose, % 960 (10) 647 (15) 898 (43) <0.001
Regular exercise, % 2823 (31) 1128 (26) 715 (35) 0.614
Smoking history (never/past/current, %) 5789/1490/1942 (63/16/21) 2038/1017/1331 (47/23/30) 986/596/487 (48/29/23) <0.001
Alcohol consumption, g/week 5.9 18.5 8.0 23.2 6.7 21.1 <0.001
ALT¼ alanine aminotransferase, AST¼ aspartate aminotransferase, BMI¼ body mass index, F¼ female, HDL¼ high-density lipoprotein,
LDL¼ low-density lipoprotein, M¼male, TyG¼ the product of fasting triglycerides and glucose levels.
test
Medicine  Volume 94, Number 27, July 2015 A Diabetes Self-Assessment Score for predicting NAFLD or NASHRESULTS
Baseline Characteristics of the Study Population
The baseline clinical and laboratory characteristics of the
study population are shown in Table 1 according to the fatty
liver condition(s) identified by abdominal ultrasonography and
NAFLD fibrosis scores. According to our data, 58.8% (9221)
of the subjectswith a normal liver showed no evidence of a fatty
liver on ultrasonography, and 28.0% (4386) of the subjects with
simple steatosis showed a fatty liver on ultrasonography and
the absence of fibrosis according to NAFLD fibrosis scores.
Subjects with steatohepatitis, a fatty liver, and intermediate or
advanced fibrosis, as assessed by NAFLD fibrosis scores,
accounted for 13.2% (2069) of the sample. Subjects with
steatosis or steatohepatitis tended to be older, more obese,
smoke more at the time of evaluation, more likely to drink
alcohol on a daily basis, and to have higher laboratory values
for metabolic factors compared to those without steatosis.
Males and those with hypertension, diabetes, or abnormal
fasting glucose levels were more likely to have steatosis or
steatohepatitis.
Predictive Power of the Korean Diabetes Score
(KDS) for NAFLD and NASH
Figure 1A presents the average values of the KDS accord-
ing to liver steatosis status as assessed by abdominal ultrasono-
graphy. The average KDS value increased significantly as the
grade of liver steatosis increased. Additionally, according to

P values were derived from ANOVA (continuous variables) or x2ultrasonagraphic data on fatty liver condition and NAFLD
fibrosis scores, simple steatosis and steatohepatitis showed
significant tendencies toward associations with increased
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.KDS values (Figure 1B). Figure 1C presents the ROC curve
for the prediction of NAFLD or NASH in the study population.
The areas under the ROC curve were 0.79 (95% CI: 0.78–0.79;
P< 0.001) and 0.81 (95% CI: 0.81–0.82; P< 0.001) for
NAFLD and NASH, respectively.
We investigated the diagnostic characteristics associated
with the use different KDS cutoff values for the prediction of
NAFLD or NASH. Use of a KDS cutoff value of 5 points to
predict NAFLD was associated with the highest values respect-
ively for males and females with regard to the following: the
Youden Index, 39 and 51; sensitivity, 79% and 85%; specificity,
60% and 66%; and AUC, 0.75 and 0.82 (Table 2). A KDS cutoff
value of 6 points was selected for the prediction of NASH, as it
was associated with a higher overall level of test accuracy
according to the Youden Index; it identified 37% of subjects at
high risk for NASH and yielded a sensitivity of 80% and 86%, a
specificity of 64% and 75%, and AUC values of 0.77 and 0.86
for males and females, respectively (Table 3).
Figure 2A and B present the ability of cutoff values of 5
and 6 on the KDS to identify subjects who had been diagnosed
with hepatic steatosis by abdominal ultrasonography and with
fibrosis by NAFLD fibrosis scores, respectively. Figure 2A
shows that 60.7% subjects with KDS values higher than 5 points
(17.4% of subjects with KDS values lower than 5, P< 0.001)
met the criteria for hepatic steatosis. The prevalence of inter-
mediate and advanced fibrosis (40.2% and 2.1%, respectively;
P< 0.001) in subjects with KDS values higher than 6 points was
significantly higher than that in those with KDS values lower
s (categorical variables).than 6 points (14.9% and 0.2%, respectively, P< 0.001;
Figure 2B). We also applied the KDS cutoff value of 6 points
to other noninvasive liver fibrosis scoring systems, such as those
www.md-journal.com | 3
FIGURE 1. Relationship between the KoreanDiabetes Score andNAFLDor NASH. (A) Average KDS values according to fatty liver grade, as
determined by hepatic ultrasound. (B) Average KDS values according to fatty liver condition, as determined by NAFLD fibrosis scores and
hepatic ultrasound. Subjects with a normal liver (N¼9221) showed no evidence of a fatty liver on ultrasonography. Simple steatosis
(N¼4386) indicates an ultrasonographically defined fatty liver in the absence of advanced fibrosis, according to NAFLD fibrosis scores.
ter
pre
on
Kim et al Medicine  Volume 94, Number 27, July 2015for FIB-4, APRI, and AAR, to compare its predictive power for
liver fibrosis with that of the NAFLD fibrosis scoring system
because we did not perform invasive liver biopsy procedures in
this study. The NAFLD fibrosis scoring system, FIB-4, APRI,
and AAR identified statistically significant different pro-
portions of subjects with hepatic fibrosis when a KDS value
higher than 6 points was used (Supplementary Figure 1, http://
links.lww.com/MD/A321).
Use of the Korean Diabetes Score and Other
Steatohepatitis (N¼2069) includes subjects with fatty liver with in
All P values are <0.001. (C) ROC curves with KDS values for the
Diabetes Score, NAFLD¼nonalcoholic fatty liver disease, NASH¼nParameters to Predict NAFLD or NASH
Multiple logistic regression analyses were performed on
KDS values and clinical and laboratory parameters to
TABLE 2. Predictive Power of the Korean Diabetes Score for NAF
Cutoff
Value
High
Risk (%)
Sensitivity
(%)
Specificity
(%)
KDS, cutoff value 4
Total (N¼ 15,676) 69 90 46
Male (N¼ 8313) 76 89 38
Female (N¼ 7363) 61 92 52
KDS, cutoff value 5
Total (N¼ 15,676) 55 81 63
Male (N¼ 8313) 60 79 60
Female (N¼ 7363) 50 85 66
KDS, cutoff value 6
Total (N¼ 15,676) 37 62 80
Male (N¼ 8313) 43 61 77
Female (N¼ 7363) 31 64 83
AUC¼ area under the receiver operating characteristic curve, KDS¼Kor
liver disease, NPV¼ negative predictive value, PPV¼ positive predictive v
4 | www.md-journal.cominvestigate important predictors of NAFLD and NASH
(Table 4). In the basic model (Model 1), the ORs that a 1-point
increase in KDS values would be associated with an increased
risk for NAFLD were 1.73 (95% CI: 1.68–1.78) in men and
2.18 (95% CI: 2.09–2.27) in women. In the comprehensive
model (Model 2), both KDS values and other parameters such as
BMI, fasting glucose, high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol, uric acid,
AST, ALT, and TyG value were independently associated with
NAFLD. In term of the risk of NASH, every 1-point increase in
mediate or advanced fibrosis, according to NAFLD fibrosis scores.
diction of NAFLD or NASH in the study population. KDS¼Korean
alcoholic steatohepatitis, ROC¼ receiver operating characteristics.KDS values was a strong predictor of the presence of this
condition (OR: 1.92, 95%CI: 1.83–2.00 in men; OR: 2.81, 95%
CI: 2.60–3.03 in women). In Model 2, KDS, BMI, fasting
LD
PPV NPV
Positive
LR
Negative
LR
Youden
Index AUC
54 87 1.66 0.22 36 0.78
60 77 1.44 0.29 27 0.75
45 94 1.91 0.16 44 0.82
61 83 2.20 0.30 44 0.78
68 73 1.98 0.35 39 0.75
51 91 2.47 0.23 51 0.82
69 75 3.15 0.47 42 0.78
73 65 2.62 0.50 38 0.75
62 84 3.79 0.43 47 0.82
ean Diabetes Score, LR¼ likelihood ratio, NAFLD¼ nonalcoholic fatty
alue.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Predictive Power of the Korean Diabetes Score for NASH
Cutoff
Value
High
Risk (%)
Sensitivity
(%)
Specificity
(%) PPV NPV
Positive
LR
Negative
LR
Youden
Index AUC
KDS, cutoff value 5
Total (N¼ 15,676) 55 92 51 22 98 1.87 0.15 43 0.81
Male (N¼ 8313) 60 91 46 25 96 1.69 0.20 37 0.77
Female (N¼ 7363) 50 95 55 19 99 2.13 0.09 51 0.86
KDS, cutoff value 6
Total (N¼ 15,676) 37 82 70 29 96 2.70 0.26 52 0.81
Male (N¼ 8313) 43 80 64 30 94 2.24 0.31 44 0.77
Female (N¼ 7363) 31 86 75 28 98 3.47 0.18 61 0.86
KDS, cutoff value 7
Total (N¼ 15,676) 18 52 87 38 92 4.08 0.55 39 0.81
Male (N¼ 8313) 22 52 84 38 90 3.14 0.58 35 0.77
Female (N¼ 7363) 13 53 91 39 95 5.92 0.51 44 0.86
AUC¼ area under the receiver operating characteristic curve, KDS¼Korean Diabetes Score, LR¼ likelihood ratio, NASH¼ nonalcoholic
tive
Medicine  Volume 94, Number 27, July 2015 A Diabetes Self-Assessment Score for predicting NAFLD or NASHglucose, AST, ALT, and TyG value were significant indepen-
dent predictors of NASH. The inclusion of KDS values and
steatohepatitis, NPV¼ negative predictive value, PPV¼ positive predicother parameters in this model produced more accurate results
with higher values of AUC than Model 1, which incorporated
only KDS values.
DISCUSSION
In this study, we validated the KDS, a noninvasive tool for
predicting NAFLD or NASH. The use of cutoff value of 5 points
on the KDS was associated with a sensitivity and specificity of
81% and 63%, respectively whereas the use of the PPV and
NPV to diagnosis or exclude NAFLD was associated with a
respective sensitivity and specificity of 61% and 83%.
Additionally, the good NPV of a score of 6 points with respect
to NASH indicated that people at high risk should be referred to
a specialist for early detection and intervention, including
further laboratory studies and imaging tests.
FIGURE 2. Proportions of subjects with hepatic steatosis (A) and fibro
Diabetes Score. KDS¼Korean Diabetes Score, NAFLD¼nonalcoholic
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.NAFLD is defined by excessive fat accumulation in the
form of cytoplasmic TG droplets, more than 5% of which are
hepatocytes, in the liver.29 The pathogenesis of NAFLD is
complex and remains poorly understood. Obesity and insulin
resistance have been well established to increase the likelihood
of developing NAFLD, and each of these factors is also
characteristic of T2D.6,7,30 Given that one element of insulin
resistance and such major contributing factors such as chronic
inflammation are mediated by oxidative stress and hepatotoxic
cytokines, T2D and NAFLD are closely associated based on
their pathogenesis.31–33 Therefore, in this study, we aimed to
investigate and validate the KDS, a useful self-report tool for
assessing the risk of diabetes, with regard to its ability to predict
NAFLD or NASH. A cutoff value of 5 points has been pre-
viously suggested to identify individuals at high risk of undiag-
value.nosed diabetes.21 Indeed, the present study confirmed the use of
cutoff points of 5 and 6 for predicting NAFLD and NASH,
respectively.
sis according to NAFLD fibrosis score (B) according to the Korean
fatty liver disease.
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NAFLD is among the most rapidly increasing diseases
worldwide, affecting one-third of adults in Western countries
and rapidly increasing in Asian nations.14 NAFLD is often
reversible and carries a good long-term prognosis, but it can
progress to NASH, which is characterized by hepatocyte
inflammation, and fibrosis, as well as dramatically increased
risks for cirrhosis, and hepatocellular carcinoma.8,12,14 There-
fore, an urgent need exists for the early detection of NAFLD or
NASH so that individuals at high risk can access early inter-
ventions to prevent the progression of these conditions. In this
context, the gold standard for diagnosing NAFLD or NASH has
been a liver biopsy, but this method has drawbacks, including
invasiveness, cost, sampling error, and intraobserver and inter-
observer variations. Indeed, performing liver biopsies on all at-
risk individuals is not possible,34 and we need to develop
noninvasive tools to replace liver biopsies. Therefore, several
simple noninvasive clinical scoring systems, such as the
NAFLD fibrosis score, FIB4, APRI, and AAR, have been
developed to diagnose or exclude liver fibrosis.15–18 The
KDS includes only 6 easily answerable questions regarding
age, family history of diabetes, personal history of hypertension,
waist circumference, smoking status, and alcohol consumption.
Our examination of different fibrosis-prediction models (FIB4,
APRI, and AAR) validated the use of a cutoff value of 6 on the
KDS for predicting NASH. We confirmed that the KDS offers
strong diagnostic power with regard to NAFLD or NASH
without requiring laboratory assays.
In terms of the AUC, the KDS demonstrated a modest level
of accuracy in predicting NAFLD (0.75 in males and 0.82 in
females) and in predicting NASH (0.77 in males and 0.86 in
females). The level of accuracy with which not only NAFLD
(AUC of 0.86 in males and 0.90 in females) but also NASH
(AUC of 0.85 in males and 0.91 in females) is identified could
be increased by combining the KDS with other clinical and
laboratory parameters. Of the laboratory parameters, BMI,
fasting glucose levels, AST, ALT, and TyG value were inde-
pendently associated with the prevalence of NASH in the entire
sample. Furthermore, we found that a significantly higher risk
of NASH than of NAFLD was associated with higher ORs for
fasting glucose levels. Prolonged exposure to hyperglycemia
can cause toxicity and induce apoptotic pathways in the liver35;
thus, diabetes is more strongly associated with worse hepatic
conditions such as NASH. In addition, the ORs for AST tended
to increase and those for ALT tended to decrease with an
increased risk of NASH. This finding is supported by a previous
study showing that AAR values greater than 1 reflect a possible
risk of the progression to NASH from NAFLD.36
Our study has several distinct strengths. First, from a
practical perspective, the KDS is a simple and convenient tool
with which laypersons can self-assess their risk of NAFLD or
NASH without laboratory assays or expense. Second, the KDS
was highly accurate in its prediction of NAFLD or NASH, and
the PPV of KDS indicated its efficacy for screening subjects at
high risk for NAFLD or NASH who should be referred for
further laboratory studies and imaging and early intervention.
The addition of laboratory parameters to the KDS will lead to
more accurate predictions of NAFLD or NASH. NAFLD or
NASH is estimated to increase 5-year direct and indirect
medical costs by 26%.37 Therefore, economic and clinical
benefit in the application of the KDS could be emphasized
in terms of public health perspective. Finally, laypersons are
Medicine  Volume 94, Number 27, July 2015able to identify and change the modifiable contributors to
NAFLD and NASH based on the components of the KDS such
as central obesity, smoking, and heavy alcohol consumption.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Thus, individuals can modify their lifestyle to improve their
health status.
The present study also has several potential limitations.
First, a liver biopsy, the standard test for diagnosing NAFLD
or NASH, was not performed. Because NAFLD was assessed
by abdominal ultrasonography, which often does not identify
early steatosis, the actual prevalence of NAFLD may have
been underestimated. Additionally, we defined NASH
indirectly, based on previously established noninvasive scor-
ing systems such as the FIB4, APRI, and AAR. Next, this was
a cross-sectional study on a Korean population, which limits
our ability to generalize our conclusions in predicting the
future development of NAFLD or NASH elsewhere. Future
investigations using a longitudinal design are needed in this
regard.
In conclusion, we investigated and validated the applica-
bility of the KDS as a powerful tool for the prediction of
NAFLD or NASH. As NAFLD, NASH, and T2D share common
characteristics, such as obesity and insulin resistance, they can
be ameliorated by early detection and intensive lifestyle modi-
fication. Therefore, the KDS could be used to alert individuals
about their risk of developing NAFLD or NASH and might
reduce the growing burden placed on society by these con-
ditions.
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